Superluminal Medicines
Biotechnology, 5900 GRN Oak Dr, Boston, Massachusetts, 55343, United States, 1-10 Employees
Phone Number: +17*********
Who is SUPERLUMINAL MEDICINES
Superluminal Medicines is a Boston-based generative biology and chemistry company developing a differentiated pipeline and revolutionizing the speed and accuracy of how medicine is create...
Read More
-
Headquarters: 5900 GRN Oak Dr, Boston, Massachusetts, 55343, United States
-
Date Founded: 2009
-
Employees: 1-10
-
Revenue: $100 Million to $250 Million
-
Active Tech Stack: See technologies
Industry: Biotechnology
SIC Code: 8043
Does something look wrong? Fix it. | View contact records from SUPERLUMINAL MEDICINES
Superluminal Medicines Org Chart and Mapping
Email
Phone
Sign in to CIENCE GO Data to uncover contact details
Free credits every month
Frequently Asked Questions Regarding Superluminal Medicines
Answer: Superluminal Medicines's headquarters are located at 5900 GRN Oak Dr, Boston, Massachusetts, 55343, United States
Answer: Superluminal Medicines's phone number is +17*********
Answer: Superluminal Medicines's official website is https://superluminalrx.com
Answer: Superluminal Medicines's revenue is $100 Million to $250 Million
Answer: Superluminal Medicines's SIC: 8043
Answer: Superluminal Medicines has 1-10 employees
Answer: Superluminal Medicines is in Biotechnology
Answer: Superluminal Medicines contact info: Phone number: +17********* Website: https://superluminalrx.com
Answer: Superluminal Medicines is a Boston-based generative biology and chemistry company developing a differentiated pipeline and revolutionizing the speed and accuracy of how medicine is created. Our platform creates candidate-ready compounds with unprecedented speed using a comprehensive combination of deep biology and chemistry expertise, machine learning, and proprietary big data infrastructure. The predict-design-test architecture accurately models protein shapes and designs highly selective compounds to target the precise structural change for therapeutic effect. Our discovery engine is powered by an industry-leading, pharmacokinetic and toxicology in silico prediction capability. With a lead program candidate expected in the near term, our proprietary pipeline validates our platform with initial programs focused on high-value GPCR targets. Were pleased to be backed by a strong network of investors including RA Capital Management, Insight Partners, NVIDIA and Gaingels.
Answer:
Premium Sales Data for Prospecting
-
Sales data across over 200M records
-
Up-to-date records (less decayed data)
-
Accurate Email Lists (real-world tested)
-
Powerful search engine and intuitive interface
Get Full Access
Sign in to CIENCE GO Data to uncover contact details
Free credits every month